Atlas Trials

Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer

Clinical trial NCT06454448 · RECRUITING

Trial details

NCT number
NCT06454448
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Adebrelimab (SHR-1316)DecitabineMetastatic Pancreatic Cancer
Start date
2024-06-15
Primary completion
2025-06-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.